The World Health Organization has designated AntiMicrobial Resistance (AMR) as one of the highest priority health and social challenges and one of the top 10 global public health threats facing humanity.
More than 5,000,000 people die of drug-resistant infections every year, 10,000,000 by 2050
BIORIDIS responds to these important challenges and needs with its quick, reliable and easy to use QE-AMR assay. QE-AMR identifies antimicrobial resistant infections through detection of bacterial mRNA or small RNA. QE-AMR assay is based on our patented LIVELMIA technology and provided as a kit for quick and easy diagnosis. QE-AMR is a first in class technology.
The development was supported also by the EIT Health InnoStars Awards